Literature DB >> 28961519

Finally a promising analgesic signal in a long-awaited new class of drugs: TRPV1 antagonist mavatrep in patients with osteoarthritis (OA).

Rolf Karlsten1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28961519     DOI： 10.1016/j.sjpain.2017.08.015

Source DB:  PubMed          Journal:  Scand J Pain        ISSN： 1877-8860


× No keyword cloud information.
  1 in total

1.  Accurate pain reporting training diminishes the placebo response: Results from a randomised, double-blind, crossover trial.

Authors:  Roi Treister; Oluwadolapo D Lawal; Jonathan D Shecter; Nevil Khurana; John Bothmer; Mark Field; Steven E Harte; Grant H Kruger; Nathaniel P Katz
Journal:  PLoS One       Date:  2018-05-24       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.